Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advil, Aleve top picks

This article was originally published in The Tan Sheet

Executive Summary

Wyeth's Advil and Bayer's Aleve were identified as pain relievers of choice for back and neck pain by half of respondents in a Spine-health.com survey of OTC product preferences. Advil was the top choice in the month-long online poll, with 26 percent (236) of the 899 voters selecting the ibuprofen, according to poll results published April 23. Naproxen sodium Aleve was picked by 24 percent (216) of respondents. McNeil's Motrin ibuprofen was the choice of 13 percent (114) and the firm's Tylenol acetaminophen was picked by 11 percent (100) of participants, Spine-health.com says. Bristol-Myers Squibb's Excedrin was chosen by 6 percent (52) of respondents and aspirin 5 percent (41). Chicago-based Spine-health.com says the poll was its first seeking consumers' preferences for OTC pain relievers, although it frequently seeks reader input...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS101581

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel